OX40–Ig reduces established illness and T cell proliferation, increases apoptosis, but does not inhibit viral clearance or recall responses. (A) Mice (n = 3) were infected with influenza virus on day 0 and treated with IgG or OX40–Ig on days 3, 4, and 5 after infection. Weight loss is expressed as percent of original weight. (B) Mice (n = 4) were infected with influenza and treated with either IgG or OX40–Ig. On days 2, 5, 7, and 11 after infection, lung tissue was homogenized and viral titre was quantified by plaque assay. (C–E) Mice (n = 4) were infected with influenza and treated with IgG or OX40–Ig as in B. 3 wk later mice were challenged with influenza and on days 2, 5, and 7 after infection, CD4+ (C), CD8+ (D), and CD8+ tetramer+ (E) T cells were enumerated in lung tissue. (F and G) Proliferating MLN CD4 and CD8 T cells (F, by BrdU incorporation) and apoptotic annexin V–stained lung cells (G) were assessed in control- or OX40–Ig-treated mice 4 and 7 d, respectively, after influenza infection. Closed symbols, IgG control; open symbols, OX40–Ig. Mean values ± SEM are shown and are representative of two separate experiments.